3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
63
Neoplasms
5
Neoplasm Metastasis
5
Carcinoma, Intraductal, Noninfiltrating
3
Breast Neoplasms, Male
3
Recurrence
2
Ovarian Neoplasms
2
Endometrial Neoplasms
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Tuberous Sclerosis
1
Squamous Cell Carcinoma of Head and Neck
1
Sexual Dysfunctions, Psychological
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Multiple Endocrine Neoplasia Type 1
1
Locoregional Recurrence
1
Hyperglycemia
1
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
HER2-positive Breast Cancer
1
Granulosa cell tumor of the ovary
1
Endometrial Stromal Tumors
1
Endometrial Hyperplasia
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
137
Cisplatin
75
Cetuximab
51
Carboplatin
49
Paclitaxel
39
Nivolumab
38
Radiotherapy
37
Docetaxel
34
Radiotherapy, Intensity-Modulated
30
Magnetic Resonance Spectroscopy
25
Specimen Handling
20
Fluorouracil
20
Platinum
14
1,2-diaminocyclohexaneplatinum II citrate
13
Taxes
12
cemiplimab
11
Radiation
11
Ipilimumab
11
atezolizumab
10
Surgical Procedures, Operative
10
Drug Therapy
10
Biopsy
9
durvalumab
8
Radiosurgery
8
130-nm albumin-bound paclitaxel
8
tislelizumab
7
Standard of Care
7
Chemoradiotherapy
7
Albumin-Bound Paclitaxel
7
Immune Checkpoint Inhibitors
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Squamous Cell Carcinoma of Head and Neck
×
exemestane
×
1 year
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled